- 收听数
- 0
- 性别
- 保密
- 听众数
- 18
- 最后登录
- 2021-3-22
- QQ
 - UID
- 765
- 阅读权限
- 20
- 帖子
- 1283
- 精华
- 0
- 在线时间
- 411 小时
- 注册时间
- 2012-10-21
- 科研币
- 7
- 速递币
- 271
- 娱乐币
- 2897
- 文献值
- 0
- 资源值
- 0
- 贡献值
- 0
|
5速递币
| 题名 | Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. | | 作者 | Mok TSK1, Kim SW1, Wu YL1, Nakagawa K1, Yang JJ1, Ahn MJ1, Wang J1, Yang JC1, Lu Y1, Atagi S1, Ponce S1, Shi X1, Rukazenkov Y1, Haddad V1, Thress KS1, Soria JC1. | | 杂志 | J Clin Oncol. 2017 Dec 20;35(36):4027-4034. | | 链接 | https://www.ncbi.nlm.nih.gov/pubmed/?term=Gefitinib+Plus+Chemotherapy+Versus+Chemotherapy+in+Epidermal+Growth+Factor+Receptor+Mutation-Positive+Non-Small-Cell+Lung+Cancer+Resistant+to+First-Line+Gefitinib+(IMPRESS)%3A+Overall+Survival+and+Biomarker+Analyses. |
|
-
总评分: 速递币 -10
查看全部评分
|
发表于 2018-6-14 15:30:33
淘帖
收藏
顶
踩
发表于 2018-6-14 15:30:34
